Physical activity and sleep in adults with arthritis
(Wiley) A new study published in Arthritis Care& Research has examined patterns of 24-hour physical activity and sleep among patients with rheumatoid arthritis, lupus, and knee osteoarthritis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 7, 2020 Category: International Medicine & Public Health Source Type: news

Lupus symptoms: What is lupus, what are the signs?
LUPUS is an inflammatory condition that can be fatal. What are the signs and symptoms? (Source: Daily Express - Health)
Source: Daily Express - Health - October 5, 2020 Category: Consumer Health News Source Type: news

President Trump ’s COVID-19 Treatment Is Already Unique. Here’s What Doctors May Do Next
Just a few hours after revealing that he tested positive for COVID-19, U.S. President Donald Trump on Friday was helicoptered to Walter Reed Army Hospital, where he will be hospitalized for at least a few days “out of an abundance of caution,” the White House says; the First Lady, Melania Trump, has also tested positive. How the President of the United States is treated for COVID-19 will likely be very different from how the 7 million-plus other Americans who have contracted the disease were taken care of, at least in some ways. To start, before Trump was hospitalized, his physician Sean Conley revealed that th...
Source: TIME: Health - October 3, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news

NIH awards Upstate professor ’s lupus clinical trial $7.2 million grant
Rheumatology Chief Andras Perl, MD, PhD, is leading the study, which is based at Upstate and involves 20 lupus centers from academic institutions around the United States. This is the first NIH-supported multi-center clinical trial led by an Upstate professor. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - October 2, 2020 Category: Universities & Medical Training Tags: News Source Type: news

Live Well By Eating Green Foods
Naturopaths have recommended the use of green foods to enhance the treatment of diseases such asthma candida lupus and HIV (Source: Disabled World)
Source: Disabled World - October 1, 2020 Category: Disability Tags: Fruit - Vegetables Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

How Does A Person Get Lupus
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 24, 2020 Category: General Medicine Source Type: news

Promising Drugs Line Up for Lupus Treatment Promising Drugs Line Up for Lupus Treatment
Systemic lupus erythematosus remains a treatment challenge, but a variety of drugs in the pipeline are set to target type I interferons, cytokines, and B cells.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - September 22, 2020 Category: Pediatrics Tags: Rheumatology News Source Type: news

Adding Belimumab Improves Renal Outcome in Lupus Nephritis
THURSDAY, Sept. 17, 2020 -- The addition of belimumab versus placebo to standard therapy increases the likelihood of a primary efficacy renal response in patients with active lupus nephritis, according to a study published in the Sept. 17 issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Companion Drug Might Help Prevent Kidney Complications of Lupus
Title: Companion Drug Might Help Prevent Kidney Complications of LupusCategory: Health NewsCreated: 9/16/2020 12:00:00 AMLast Editorial Review: 9/17/2020 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - September 17, 2020 Category: Anesthesiology Source Type: news

Companion Drug Might Help Prevent Kidney Complications of Lupus
WEDNESDAY, Sept. 16, 2020 -- Adding a newer drug to standard therapy might help control kidney complications caused by the autoimmune disease lupus, a new clinical trial suggests. The researchers found that adding the drug, called belimumab,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 16, 2020 Category: General Medicine Source Type: news

COVID-19 Ills No Greater for Those With Lupus, RA
People with lupus or rheumatoid arthritis aren't at increased risk of hospitalization from COVID-19. (Source: WebMD Health)
Source: WebMD Health - September 4, 2020 Category: Consumer Health News Source Type: news

Some Lupus Erythematosus Cases Tied to Drug Exposure
FRIDAY, Sept. 4, 2020 -- Some cases of subacute cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) are drug-induced, according to a study published online Sept. 2 in JAMA Dermatology. Jeanette Halskou Haugaard, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 4, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 Ills No Greater for Those With Lupus, Rheumatoid Arthritis
FRIDAY, Sept. 4, 2020 -- People with lupus aren't at increased risk of hospitalization from COVID-19 due to steroidal medications they take to reduce immune system activity, a new study finds. And a related study found that people with inflammatory... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 4, 2020 Category: General Medicine Source Type: news

COVID-19 Ills No Greater for Those With Lupus, Rheumatoid Arthritis
Title: COVID-19 Ills No Greater for Those With Lupus, Rheumatoid ArthritisCategory: Health NewsCreated: 9/4/2020 12:00:00 AMLast Editorial Review: 9/4/2020 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 4, 2020 Category: Rheumatology Source Type: news

Menieres Disease Vs Lupus
Meniere's Disease Vs. Lupus (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 2, 2020 Category: General Medicine Source Type: news

Risk for COVID-19 Hospitalization Follows Usual Pattern in Lupus
THURSDAY, Aug. 27, 2020 -- For patients with systemic lupus erythematosus (SLE), predictors of hospitalization include race, presence of comorbidity, and body mass index, according to a study published online July 26 in Arthritis&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 27, 2020 Category: Pharmaceuticals Source Type: news

Most adults with lupus or common types of arthritis have similar risks of getting admitted to hospital as other COVID-19 patients
(NYU Langone Health / NYU School of Medicine) Most adults with systemic lupus erythematosus (SLE) are not at increased risk of hospitalization from COVID-19 due to medications used to dampen their altered immune system, the cause of their disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 25, 2020 Category: International Medicine & Public Health Source Type: news

Anti-malaria drug hydroxychloroquine does NOT prevent people from contracting coronavirus
A new study found about 34.6% of patients with lupus and/or rheumatoid arthritis taking the drug contracted coronavirus, just about as many as those with the conditions who didn't fall ill. (Source: the Mail online | Health)
Source: the Mail online | Health - August 19, 2020 Category: Consumer Health News Source Type: news

New study: Hydroxychloroquine ineffective as a preventive antiviral against COVID-19
(Case Western Reserve University) Researchers at Case Western Reserve University have added to the growing body of understanding about how hydroxychloroquine (HCQ) is not a possible defense against COVID-19. Specifically, they found that HCQ is not effective in preventing COVID-19 in patients with lupus and rheumatoid arthritis (RA), suggesting a broader interpretation of HCQ as ineffective preventive medicine for the general population. Their findings were recently published in the Annals of the Rheumatic Diseases. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 17, 2020 Category: Infectious Diseases Source Type: news

Assessment of lupus anticoagulant positivity in patients with COVID-19
(JAMA Network) How common lupus anticoagulant (LA) positivity is in patients with COVID-19 was assessed in this observational study, which also examined the association of LA positivity with patient outcomes. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 12, 2020 Category: Infectious Diseases Source Type: news

Rheumatoid Arthritis vs. Lupus: Differences and Similarities
Title: Rheumatoid Arthritis vs. Lupus: Differences and SimilaritiesCategory: Procedures and TestsCreated: 8/6/2020 12:00:00 AMLast Editorial Review: 8/6/2020 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - August 6, 2020 Category: Rheumatology Source Type: news

Difference Between Rheumatoid Arthritis vs Lupus
What Is the Difference Between Rheumatoid Arthritis and Lupus? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 3, 2020 Category: General Medicine Source Type: news

Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis
VICTORIA, British Columbia& ROCKVILLE, Md.--(BUSINESS WIRE) July 21, 2020 -- Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the“Company”), a late-stage clinical biopharmaceutical company focused on... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 21, 2020 Category: Drugs & Pharmacology Source Type: news

Lupus Drug Prevents Low Heartbeat in High-Risk Newborns: Study
Title: Lupus Drug Prevents Low Heartbeat in High-Risk Newborns: StudyCategory: Health NewsCreated: 7/17/2020 12:00:00 AMLast Editorial Review: 7/20/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 20, 2020 Category: Cardiology Source Type: news

Lupus Drug Prevents Low Heartbeat in High-Risk Newborns: Study
FRIDAY, July 17, 2020 -- A drug used to treat lupus and malaria -- hydroxychloroquine -- reduced by half the risk of a potentially fatal heart condition in newborns who were at high risk for it. The condition -- known as congenital heart block (CHB)... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 17, 2020 Category: General Medicine Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

CHOP-pioneered spatial mapping method pinpoints potential new therapeutic targets in lupus
(Children's Hospital of Philadelphia) A team of researchers from Children's Hospital of Philadelphia (CHOP) used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 8, 2020 Category: International Medicine & Public Health Source Type: news

What Are the 4 Types of Lupus?
Title: What Are the 4 Types of Lupus?Category: Diseases and ConditionsCreated: 7/4/2020 12:00:00 AMLast Editorial Review: 7/4/2020 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 4, 2020 Category: Rheumatology Source Type: news

What Is Usually the First Sign of Lupus?
Title: What Is Usually the First Sign of Lupus?Category: Diseases and ConditionsCreated: 7/1/2020 12:00:00 AMLast Editorial Review: 7/1/2020 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 1, 2020 Category: Rheumatology Source Type: news

What Are the 12 Symptoms of Lupus?
Title: What Are the 12 Symptoms of Lupus?Category: Diseases and ConditionsCreated: 7/1/2020 12:00:00 AMLast Editorial Review: 7/1/2020 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 1, 2020 Category: Rheumatology Source Type: news

What Are the Four Types of Lupus?
Title: What Are the Four Types of Lupus?Category: Diseases and ConditionsCreated: 7/1/2020 12:00:00 AMLast Editorial Review: 7/1/2020 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 1, 2020 Category: Rheumatology Source Type: news

Systemic lupus erythematosus incurs high healthcare costs in US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2020 Category: Drugs & Pharmacology Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, Pa., June 26, 2020 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Ery... Biopharmaceuticals Janssen Pharmaceutical, Johnson & Johnson, STELARA, ustekinumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2020 Category: Pharmaceuticals Source Type: news

What Causes Bradycardia?
Discussion Bradycardia is a heart rate below what the lowest value that is normal for age. Infants and children have higher heart rates that slowly decrease with age to adult levels. It is usually noted as an incidental finding because of increased vagal tone. Reasons for cardiology referral include associated heart murmur, syncope especially if associated with exercise or unusual triggers, other signs such as chest pain or palpitations, family history of sudden cardiac death, congenital heart disease or familial heart disease, bradycardic medication use, or unusual symptoms associated with the concern. Severe bradycardia ...
Source: PediatricEducation.org - June 22, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Seattle immunology biotech signs $60M deal for its lupus drug
Alpine has the potential to receive an additional $805 million if the drug meets certain milestones. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 19, 2020 Category: Biotechnology Authors: Megan Campbell Source Type: news

Lupus Therapies Continue to Evolve
May is National Lupus Awareness Month, a good time to think about lupus and the challenges it presents to patients. Learn about this chronic, autoimmune disease and the promise of future therapies. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 17, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

‘India not to stop hydroxychloroquine treatment in mild cases'
​​HCQ, currently used to treat lupus and rheumatoid arthritis, has split world opinion on its use in Covid-19 management, even as India said the decision was “taken based on risk-benefit assessment.” (Source: The Economic Times)
Source: The Economic Times - June 16, 2020 Category: Consumer Health News Source Type: news

The FDA Revoked Emergency Use Authorization for Hydroxychloroquine, Citing New Evidence
The U.S. Food and Drug Administration (FDA) announced today that it is revoking the emergency use authorization for hydroxychloroquine and chloroquine, citing a lack of evidence that these drugs are effective for COVID-19. Early on in the pandemic, doctors scrambling to find a way to treat the disease widely prescribed hydroxychloroquine to their sickest patients, based on thin evidence from a handful of relatively weak studies. However, recent research has made it increasingly clear that the drug is likely ineffective against the disease, and that it carries a risk of significant side effects, including heart problems. ...
Source: TIME: Health - June 15, 2020 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 Source Type: news

The FDA Revokes Emergency Use Authorization for Hydroxychloroquine, Citing New Evidence
The U.S. Food and Drug Administration (FDA) announced today that it is revoking the emergency use authorization for hydroxychloroquine and chloroquine, citing a lack of evidence that these drugs are effective for COVID-19. Early on in the pandemic, doctors scrambling to find a way to treat the disease widely prescribed hydroxychloroquine to their sickest patients, based on thin evidence from a handful of relatively weak studies. However, recent research has made it increasingly clear that the drug is likely ineffective against the disease, and that it carries a risk of significant side effects, including heart problems. ...
Source: TIME: Health - June 15, 2020 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 Source Type: news

Novel Antibody Improves Renal Outcomes in Lupus Nephritis Novel Antibody Improves Renal Outcomes in Lupus Nephritis
A monoclonal antibody that blocks B-cell activity improves renal outcomes when added to standard maintenance therapy in patients with lupus nephritis, a large phase 3 trial shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2020 Category: Consumer Health News Tags: Nephrology News Source Type: news

Study Tests a Simpler Low Disease Activity Measure for Lupus Study Tests a Simpler Low Disease Activity Measure for Lupus
An alternative disease activity index for patients with systemic lupus erythematosus yields results similar to the Lupus Low Disease Activity State and may be easier to apply.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

What Causes Free Peritoneal Fluid?
Discussion Peritoneal fluid is normal. It decreases the friction of the peritoneum covering abdominal and pelvic organs and helps to protect them and allow their movement. A normal amount of peritoneal fluid is expected on radiological evaluation. Increased peritoneal fluid is a continuum and is concerning as a wide variety of pathological causes are associated with it such as abdominal trauma and appendicitis. At the far end of the scale is ascites that is the accumulation of free fluid more than 25 ml. It is usually associated with abdominal distension but fluid must accumulate before distension can occur and therefore i...
Source: PediatricEducation.org - June 8, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Peninsula biotech's stock soars 73% on results of lupus trial
A Peninsula company spun out of Amgen Inc. after its acquisition of Onyx Pharmaceuticals saw its stock climb 73% Thursday on results from a study of its lead drug in people with a type of lupus. Kezar Life Sciences Inc. (NASDAQ: KZR) said people given the drug, called KZR-616, showed improvements across seven measures of disease activity in a Phase Ib study in systemic lupus erythematosus, a disease in which the immune system attacks healthy tissue and affects the skin, joins, kidneys, br ain and… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 4, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Peninsula biotech's stock soars 73% on results of lupus trial
A Peninsula company spun out of Amgen Inc. after its acquisition of Onyx Pharmaceuticals saw its stock climb 73% Thursday on results from a study of its lead drug in people with a type of lupus. Kezar Life Sciences Inc. (NASDAQ: KZR) said people given the drug, called KZR-616, showed improvements across seven measures of disease activity in a Phase Ib study in systemic lupus erythematosus, a disease in which the immune system attacks healthy tissue and affects the skin, joins, kidneys, br ain and… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 4, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

WHO Resumes Study of Hydroxychloroquine for Treating COVID-19
On June 3, the World Health Organization (WHO) resumed a study looking into whether the malaria drug hydroxychloroquine could be effective in treating COVID-19. Last week, the WHO temporarily stopped people from enrolling in the trial, part of a larger study called Solidarity that is investigating a number of different potential coronavirus therapies, over concerns about the hydroxychloroquine’s adverse effects on the heart. That followed the publication of a Lancet study on May 22, involving more than 96,000 people, which found that the drug did not improve survival among patients hospitalized with COVID-19, and tha...
Source: TIME: Health - June 3, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

One-Third of Lupus Patients Have Trouble Refilling Hydroxychloroquine
WEDNESDAY, June 3, 2020 -- More than one-third of patients with lupus have experienced significant issues filling their hydroxychloroquine prescription during the COVID-19 pandemic, according to the results of a survey released May 28 by the Lupus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 3, 2020 Category: Pharmaceuticals Source Type: news

Hydroxychloroquine criticism is all about protecting Big Pharma profits
(Natural News) If you only listened to the mainstream media, you might think hydroxychloroquine is a risky medication that does nothing to help COVID-19 patients, but the truth is that it’s a drug that has been used for 65 years to prevent and treat illnesses like lupus, malaria and rheumatoid arthritis and has been officially... (Source: NaturalNews.com)
Source: NaturalNews.com - June 3, 2020 Category: Consumer Health News Source Type: news

First do no harm -- researchers urge halt in prescribing hydroxycholoroquine for COVID-19
(Florida Atlantic University) Researchers urge a moratorium on prescribing chloroquine or hydroxychloroquine, with or without azithromycin, to treat or prevent COVID-19, and caution that the reassuring safety profile of hydroxychloroquine may be more apparent than real. Safety data derive from decades of prescriptions by clinicians, primarily for their patients with lupus and rheumatoid arthritis, both of which are of greater prevalence in younger and middle age women, who are at very low risk of fatal heart outcomes due to hydroxychloroquine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 3, 2020 Category: Infectious Diseases Source Type: news